Statins and colorectal cancer

Paul Lochhead, Andrew T Chan

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, more commonly referred to as statins, comprise a family of lipid-lowering drugs that are prescribed on a global scale on account of their demonstrated safety and efficacy in reducing mortality from cardiovascular disease. Beyond their potent pharmacologic inhibition of cholesterol biosynthesis, statins appear to have pleiotropic effects, including modulation of cell growth, apoptosis, and inflammation. Through modulation of these pathways, statins have the potential to influence a wide range of disease processes, including cancer. Much attention has focussed on the association between statins and colorectal cancer, raising the prospect that these well-tolerated compounds could form the basis of future chemopreventive strategies. Herein we review the epidemiologic, clinical, and pre-clinical data relevant to statins and colorectal neoplasia, and discuss the current status and future potential of statins as chemopreventive agents.
Original languageEnglish
Pages (from-to)109-118
Number of pages10
JournalClinical Gastroenterology and Hepatology
Volume11
Issue number2
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Colorectal Neoplasms
Neoplasms
Oxidoreductases
Cardiovascular Diseases
Cholesterol
Apoptosis
Inflammation
Lipids
Safety
Mortality
Growth
Pharmaceutical Preparations

Keywords

  • statin
  • colon
  • rectum
  • adenoma
  • chemoprevention

Cite this

Statins and colorectal cancer. / Lochhead, Paul; Chan, Andrew T.

In: Clinical Gastroenterology and Hepatology, Vol. 11, No. 2, 02.2013, p. 109-118.

Research output: Contribution to journalArticle

Lochhead, Paul ; Chan, Andrew T. / Statins and colorectal cancer. In: Clinical Gastroenterology and Hepatology. 2013 ; Vol. 11, No. 2. pp. 109-118.
@article{7f5f36cad07247afbabc7118869d6e1c,
title = "Statins and colorectal cancer",
abstract = "The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, more commonly referred to as statins, comprise a family of lipid-lowering drugs that are prescribed on a global scale on account of their demonstrated safety and efficacy in reducing mortality from cardiovascular disease. Beyond their potent pharmacologic inhibition of cholesterol biosynthesis, statins appear to have pleiotropic effects, including modulation of cell growth, apoptosis, and inflammation. Through modulation of these pathways, statins have the potential to influence a wide range of disease processes, including cancer. Much attention has focussed on the association between statins and colorectal cancer, raising the prospect that these well-tolerated compounds could form the basis of future chemopreventive strategies. Herein we review the epidemiologic, clinical, and pre-clinical data relevant to statins and colorectal neoplasia, and discuss the current status and future potential of statins as chemopreventive agents.",
keywords = "statin, colon, rectum, adenoma, chemoprevention",
author = "Paul Lochhead and Chan, {Andrew T}",
note = "Copyright {\circledC} 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.",
year = "2013",
month = "2",
doi = "10.1016/j.cgh.2012.08.037",
language = "English",
volume = "11",
pages = "109--118",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Statins and colorectal cancer

AU - Lochhead, Paul

AU - Chan, Andrew T

N1 - Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

PY - 2013/2

Y1 - 2013/2

N2 - The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, more commonly referred to as statins, comprise a family of lipid-lowering drugs that are prescribed on a global scale on account of their demonstrated safety and efficacy in reducing mortality from cardiovascular disease. Beyond their potent pharmacologic inhibition of cholesterol biosynthesis, statins appear to have pleiotropic effects, including modulation of cell growth, apoptosis, and inflammation. Through modulation of these pathways, statins have the potential to influence a wide range of disease processes, including cancer. Much attention has focussed on the association between statins and colorectal cancer, raising the prospect that these well-tolerated compounds could form the basis of future chemopreventive strategies. Herein we review the epidemiologic, clinical, and pre-clinical data relevant to statins and colorectal neoplasia, and discuss the current status and future potential of statins as chemopreventive agents.

AB - The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, more commonly referred to as statins, comprise a family of lipid-lowering drugs that are prescribed on a global scale on account of their demonstrated safety and efficacy in reducing mortality from cardiovascular disease. Beyond their potent pharmacologic inhibition of cholesterol biosynthesis, statins appear to have pleiotropic effects, including modulation of cell growth, apoptosis, and inflammation. Through modulation of these pathways, statins have the potential to influence a wide range of disease processes, including cancer. Much attention has focussed on the association between statins and colorectal cancer, raising the prospect that these well-tolerated compounds could form the basis of future chemopreventive strategies. Herein we review the epidemiologic, clinical, and pre-clinical data relevant to statins and colorectal neoplasia, and discuss the current status and future potential of statins as chemopreventive agents.

KW - statin

KW - colon

KW - rectum

KW - adenoma

KW - chemoprevention

U2 - 10.1016/j.cgh.2012.08.037

DO - 10.1016/j.cgh.2012.08.037

M3 - Article

C2 - 22982096

VL - 11

SP - 109

EP - 118

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 2

ER -